Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Immunoassay Control Monitors 54 Analytes Including Vitamin D

By Labmedica International staff writers
Posted on 03 Jan 2012
An immunoassay premium plus control is designed to monitor the accuracy and precision of up to 54 analytes including 25-OH Vitamin D and 1-25(OH)2 Vitamin D.

Specific target values are also provided for a wide range of fertility hormones, thyroid hormones, steroid hormones, kidney function tests, therapeutic drugs, and tumor markers. The inclusion of routinely run tumor markers and parameters such as intact parathyroid hormone (PTH) allows quality control practices to be simplified by dramatically reducing the number of controls used in the laboratory with the added benefit of cost and time savings.

The Acusera immunoassay premium plus control is being offered by Randox (Crumlin, United Kingdom). It has a shelf life of up to four years and is suitable for long-term quality control (QC) monitoring. It can significantly reduce the costs and problems associated with changing lot numbers.

In addition to low Vitamin B12 levels, the Randox Immunoassay Premium and Premium Plus controls contain ultra low levels of ferritin and thyroid stimulating hormone (TSH) as well as other vitamins. The control also contains many of the routinely run tumor markers including alpha-fetoprotein (AFP), CA15-3, CA19-9, CA-125, CEA, prostate specific antigen (PSA), and Free-PSA.

Vitamin D can also be found in the Randox RIQAS Immunoassay EQA program. RIQAS (Randox International Quality Assessment Scheme) is a large global EQA scheme with more than 20,000 participants in over 100 countries worldwide.

Related Links:

Randox



DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG
Dubai Bio Expo-2015

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.